Bioethics International (BEI) is dedicated to advancing patient and global health by ensuring that pharmaceutical innovation is responsible and patient-centered. The organization works to develop, monitor, and disseminate industry benchmarks for ethics, equity, and social responsibility in healthcare, involving stakeholders such as physicians, patients, and regulators.
2006
87-0774767
$740.7 thousand
This organization contributes to the following United Nations Sustainable Development Goals. See the SDG page for more information.
The Good Pharma Scorecard ranks pharmaceutical and biotechnology companies on their bioethics and social responsibility performance, focusing on patient-centric issues that affect public health.
Join us in June 2024 for a comprehensive discussion on metrics for success in patient-centric bioethics and health equity in the pharmaceutical sector.
An annual discussion where patients and healthcare professionals share insights on bioethics and responsibilities in the pharmaceutical industry.
September 15, 2023
This year’s roundtable focuses on metrics + strategies for advancing bioethics, patient-centricity + health equity across the bio-pharmaceutical sector.
October 19, 2022 — October 20, 2022
Keynote at the National Health Council's symposium discussing health equity and patient engagement.
July 17, 2023
An annual gathering featuring insights from industry leaders on best practices for clinical trial transparency.
June 24, 2024
Join us in June 2024 for a comprehensive discussion on metrics for success in patient-centric bioethics and health equity in the pharmaceutical sector.
Learn MoreOverall Score
49
30
/100
Program Expense Ratio
87.26%
18
/20
Program Revenue Growth
0.00%
2
/20
Leverage Ratio
0.6055
6
/20
Working Capital Ratio
265.9
2
/20
Fundraising Efficiency
0
2
/20
Fiscal Year:2022
Source:Source: Self-reported by organization
Category | Amount | Percentage |
---|---|---|
Contributions, Gifts, and Grants | 0 | 0.00% |
Program Services | 0 | 0.00% |
Investment Income | 0 | 0.00% |
Sales of Non-Inventory Assets | 0 | 0.00% |
Other Notable Sources | 0 | 0.00% |
Total Revenue | 0 | 100.00% |
Science & Tech
Science & Tech SocietyScience & Tech
Science & Tech SocietyScience & Tech
Science & Tech SocietyScience & Tech
Science & Tech SocietyScience & Tech
Science & Tech Society